Mens Sana Monographs
REVIEW ARTICLE
Year
: 2012  |  Volume : 10  |  Issue : 1  |  Page : 45--69

Drug therapy of attention deficit hyperactivity disorder: Current trends


Avinash De Sousa1, Gurvinder Kalra2 
1 Consultant Psychiatrist & Founder Trustee, Desousa Foundation, Carmel, 18, St. Francis Avenue, Off SV Road, Santacruz West, Mumbai-400 054, Maharashthra, India
2 Assistant Professor, Department of Psychiatry, Lokmanya Tilak Medical College & General Hospital, Sion, Mumbai-400 022, Maharashthra, India

Correspondence Address:
Avinash De Sousa
Carmel, 18, St. Francis Avenue, Off SV Road, Santacruz West, Mumbai-400 054, Maharashthra
India

Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as a-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.


How to cite this article:
De Sousa A, Kalra G. Drug therapy of attention deficit hyperactivity disorder: Current trends.Mens Sana Monogr 2012;10:45-69


How to cite this URL:
De Sousa A, Kalra G. Drug therapy of attention deficit hyperactivity disorder: Current trends. Mens Sana Monogr [serial online] 2012 [cited 2020 Aug 11 ];10:45-69
Available from: http://www.msmonographs.org/article.asp?issn=0973-1229;year=2012;volume=10;issue=1;spage=45;epage=69;aulast=De;type=0